EARNEST Partners’s Nektar Therapeutics NKTR Stock Holding History

EARNEST Partners’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-6	Closed	-$49	–	816
2023 Q3	$49	Hold	6	–	–	﹤0.01%	1159
2023 Q2	$48	Hold	6	–	–	﹤0.01%	1168
2023 Q1	$58	Hold	6	–	–	﹤0.01%	1165
2022 Q4	$188	Hold	6	–	–	﹤0.01%	1156
2022 Q3	$0	Hold	6	–	–	﹤0.01%	1153
2022 Q2	$0	Hold	6	–	–	﹤0.01%	1176
2022 Q1	$0	Hold	6	–	–	﹤0.01%	1174
2021 Q4	$1K	Hold	6	–	–	﹤0.01%	1115
2021 Q3	$1K	Hold	6	–	–	﹤0.01%	1119
2021 Q2	$1K	Hold	6	–	–	﹤0.01%	1122
2021 Q1	$2K	Hold	6	–	–	﹤0.01%	1045
2020 Q4	$1K	Hold	6	–	–	﹤0.01%	1122
2020 Q3	$1K	Hold	6	–	–	﹤0.01%	1081
2020 Q2	$2K	Hold	6	–	–	﹤0.01%	949
2020 Q1	$1K	Hold	6	–	–	﹤0.01%	1017
2019 Q4	$2K	Hold	6	–	–	﹤0.01%	1013
2019 Q3	$2K	Hold	6	–	–	﹤0.01%	998
2019 Q2	$3K	Hold	6	–	–	﹤0.01%	931
2019 Q1	$3K	Hold	6	–	–	﹤0.01%	930
2018 Q4	$3K	Hold	6	–	–	﹤0.01%	886
2018 Q3	$5K	Hold	6	–	–	﹤0.01%	784
2018 Q2	$4K	Buy	+6	New	+$6.92K	﹤0.01%	859

Other funds holding NKTR

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

EARNEST Partners's NKTR Position: Q4 2023 in Review

EARNEST Partners sold out of Nektar Therapeutics (NKTR) in Q4 2023, closing a stake of 6 shares — an estimated $49 sold.

EARNEST Partners first reported a position in NKTR in Q2 2018 and held it in 22 quarters. The position peaked at $5K in Q3 2018. 125 funds tracked by Wall St. Rank hold NKTR as of Q4 2023.

EARNEST Partners reported no remaining Nektar Therapeutics position as of Q4 2023 after selling out during the quarter.
EARNEST Partners sold 6 Nektar Therapeutics shares in Q4 2023, an estimated $49.
EARNEST Partners first reported a position in Nektar Therapeutics in Q2 2018 and held it in 22 quarters.
EARNEST Partners's Nektar Therapeutics position peaked at $5K in Q3 2018.
125 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2023.

Based on EARNEST Partners's 13F filing for Q4 2023, filed 14 Feb 2024.